This GT Alert highlights some of the key consumer products bills in New York that companies may want to watch.
Continue Reading 2026 New York Consumer Products Legislation: Key Bills to Watch
Self-Driving Vehicles Liability Assignment in Crashes and Violations
The rise of autonomous vehicles has upended traditional fault frameworks, shifting liability from human drivers toward manufacturers, software developers, and fleet operators. This GT Advisory examines the federal and state regulatory landscape, insurance considerations, and unresolved legal questions shaping accountability for self-driving car incidents.
Continue Reading Self-Driving Vehicles Liability Assignment in Crashes and Violations
Expert Testimony in the Age of Generative AI: Recent Case Developments
Much has been written about the risks of lawyers relying on generative artificial intelligence (Gen. AI) to draft briefs—especially when unchecked citations turn out to be hallucinated. But lawyer briefs are not the only documents that demand scrutiny. As the cases below show, lawyers must also carefully review their experts’ affidavits, declarations, and reports before submitting them to other parties or the court.
Continue Reading Expert Testimony in the Age of Generative AI: Recent Case Developments
Circuit Court Rejects Illinois Lawmakers’ Challenge to Senate Bill 328’s Expansion of Toxic-Tort Jurisdiction
Gov. Pritzker signed Senate Bill 328 into law on Aug. 15. A circuit court recently dismissed one challenge to the law brought by various Illinois lawmakers.
Continue Reading Circuit Court Rejects Illinois Lawmakers’ Challenge to Senate Bill 328’s Expansion of Toxic-Tort Jurisdiction
Illinois Senate Bill 328 May Impact Foreign Corporations in Toxic Tort Cases
Amid the waning hours of its spring legislative session, the Illinois General Assembly passed a bill which, if the governor signs, would significantly expand Illinois courts’ jurisdictional reach to foreign corporations in toxic tort litigation.
Continue Reading Illinois Senate Bill 328 May Impact Foreign Corporations in Toxic Tort Cases
Extended Producer Responsibility Packaging and Greenwashing Laws Expand, Targeting Plastic Reduction and Recycling Management
Extended Producer Responsibility (EPR) laws continue to proliferate in the United States, presenting significant operational challenges for consumer packaged goods companies. Earlier in 2024, Minnesota became the sixth state to enact a broad packaging EPR law, joining California, Colorado, Maine, Oregon, and Maryland in the emerging trend of states imposing responsibility for end-of-life management for
Trademark Owner Liable to Consumer for Product Defect, European Court of Justice Rules
A case that originated in Finland concerned liability for a defective product and the concept of “producer” under EU trademark law. A coffee machine (the Philips Saeco Xsmall HD8743/11) manufactured by Saeco, a Romanian subsidiary of Philips, caught fire. The machine contained trademarks of both Saeco and Philips. The unlucky consumer that got a fire
Strategies for Defending Issue Class Actions
Historically, plaintiffs seeking monetary damages and wishing to pursue their case as a class action have sought certification under Federal Rule of Civil Procedure 23(b)(3), but this has become increasingly difficult. In recent years, there has therefore been a rise in the invocation of Rule 23(c)(4) at the class certification stage, often as an alternative
The Illinois Supreme Court Strikes a Blow to Litigation Tourism in the State
The Illinois Supreme Court issued a decisive blow on June 4, 2020, to destination plaintiffs seeking to forum-shop in Illinois. Following the U.S. Supreme Court’s lead, the Illinois top court held in Christy Rios et al., v. Bayer Corporation et al., 2020 IL 125020 (June 4, 2020), that Illinois lacks personal jurisdiction over nonresident
FDA and FTC Warn Companies for Unauthorized Coronavirus Disease 2019 (COVID-19) Claims
On March 6, 2020, the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) jointly issued seven warning letters to companies making alleged unauthorized claims related to the prevention or treatment of the Coronavirus Disease 2019 (COVID-19). In addition to issuing the joint warning letters, the FDA issued a press release announcing the